摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-1-(3-Aminopiperidin-1-yl)ethanone | 1207602-55-8

中文名称
——
中文别名
——
英文名称
(S)-1-(3-Aminopiperidin-1-yl)ethanone
英文别名
1-[(3S)-3-aminopiperidin-1-yl]ethanone
(S)-1-(3-Aminopiperidin-1-yl)ethanone化学式
CAS
1207602-55-8
化学式
C7H14N2O
mdl
MFCD09264572
分子量
142.201
InChiKey
IXINAEREEWKDJW-ZETCQYMHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.7
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.86
  • 拓扑面积:
    46.3
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    (S)-1-(3-Aminopiperidin-1-yl)ethanone2-[[5-(2-Fluoropyridin-3-yl)pyrazolo[3,4-b]pyrazin-1-yl]methoxy]ethyl-trimethylsilaneN,N-二异丙基乙胺 作用下, 以 N-甲基吡咯烷酮 为溶剂, 反应 16.0h, 以86%的产率得到1-[(3S)-3-[[3-[1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyrazin-5-yl]pyridin-2-yl]amino]piperidin-1-yl]ethanone
    参考文献:
    名称:
    INHIBITORS OF JAK
    摘要:
    本发明涉及使用式I的新化合物,其中变量m、n、p、q、Q、r、R、R′、X、X′、Y、Z1、Z2和Z3如本文所述定义,这些化合物抑制JAK并且对于治疗自身免疫和炎症性疾病有用。
    公开号:
    US20110059118A1
  • 作为产物:
    描述:
    (S)-3-Boc-氨基哌啶三乙胺 作用下, 以 甲醇二氯甲烷 为溶剂, 反应 5.0h, 生成 (S)-1-(3-Aminopiperidin-1-yl)ethanone
    参考文献:
    名称:
    [EN] RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF
    [FR] INHIBITEURS DE RAS, COMPOSITIONS ET PROCÉDÉS D'UTILISATION DE CEUX-CI
    摘要:
    There is provided a compound of formula (I), and its use for inhibiting RAS (wild type or mutant), for example HRAS, NRAS, and/or KRAS, and for the prevention or treatment of a disease or disorder associated with abnormal RAS activity, for example abnormal RAS activity caused by a mutation in RAS, including cancers with a mutated RAS. (I)
    公开号:
    WO2023060362A1
点击查看最新优质反应信息

文献信息

  • HETEROCYCLIC ANTIVIRAL COMPOUNDS
    申请人:Chin Elbert
    公开号:US20100081658A1
    公开(公告)日:2010-04-01
    Compounds having the formula I wherein R 1 , R 2a , R 2b , R 2c , R 3 , Y and p are as defined herein and C2-C3 is a single or double bond are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    具有以下公式的化合物 I,其中 R1、R2a、R2b、R2c、R3、Y 和 p 的定义如本文所述,且 C2-C3 是单键或双键的化合物是丙型肝炎病毒NS5b聚合酶抑制剂。还公开了用于治疗HCV感染和抑制HCV复制的组合物和方法。
  • [EN] NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO<br/>[FR] NOUVEAUX COMPOSÉS, COMPOSITION PHARMACEUTIQUE ET PROCÉDÉS CORRESPONDANTS
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2010149684A1
    公开(公告)日:2010-12-29
    New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein R1, R2, R3, n, p, q, and Ar are as defined herein, including stereoisomers, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising a compound of this invention, as well as methods relating to the use thereof in a patient in need thereof.
    本发明公开了具有结构(I)的新化合物,其在患者中治疗各种与代谢相关的病症具有实用性:其中R1、R2、R3、n、p、q和Ar如本文所定义,包括立体异构体、溶剂合物和药学上可接受的盐。还公开了包含本发明化合物的药物组合物,以及关于其在有需要的患者中使用的方法。
  • [EN] PYRROLOPYRIMIDINECARBOXAMIDES<br/>[FR] PYRROLOPYRIMIDINE CARBOXAMIDES
    申请人:NYCOMED GMBH
    公开号:WO2009106531A1
    公开(公告)日:2009-09-03
    The compounds of Formula (I) wherein R1, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the N-oxides of the compounds and the salts thereof and the stereoisomers of the compounds, the salts, the N-oxides of the compounds and the N-oxides of the salts thereof are effective inhibitors of the type 5 phosphodiesterase.
    Formula(I)中的化合物,其中R1、R21、R22、R23、R24、Y和R3的含义如描述中所述,其盐,化合物的N-氧化物及其盐,化合物的立体异构体,盐,化合物的N-氧化物及其盐的N-氧化物是有效的第5型磷酸二酯酶抑制剂。
  • [EN] 6-BENZYL-2,3,4,7-TETRAHYDRO-INDOLO[2,3-C]QUINOLINE COMPOUNDS<br/>[FR] COMPOSÉS DE 6-BENZYL-2,3,4,7-TÉTRAHYDRO-INDOLO[2,3-C]QUINOLÉINE
    申请人:NYCOMED GMBH
    公开号:WO2010015585A1
    公开(公告)日:2010-02-11
    The present invention pertains to 6-benzyl-2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds of formula (I), as well as the resulting pharmaceutical compositions, and their use in the treatment or prophylaxis of diseases alleviated by inhibition of type 5 phosphodiesterases. Furthermore, the present invention pertains to the methods of manufacturing these 6-benzyl-2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds.
    本发明涉及式(I)的6-苄基-2,3,4,7-四氢吲哚[2,3-c]喹啉化合物,以及由此产生的药物组合物,以及它们在治疗或预防通过抑制5型磷酸二酯酶缓解的疾病中的用途。此外,本发明涉及制造这些6-苄基-2,3,4,7-四氢吲哚[2,3-c]喹啉化合物的方法。
  • [EN] BENZYL-SUBSTITUTED TETRACYCLIC HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES TÉTRACYCLIQUES SUBSTITUÉS PAR BENZYLE
    申请人:NYCOMED GMBH
    公开号:WO2011015523A1
    公开(公告)日:2011-02-10
    The present invention pertains to Benzyl-substituted tetracyclic heterocyclic compounds, as well as the resulting pharmaceutical compositions, and their use in the treatment or prophylaxis of diseases alleviated by inhibition of type 5 phosphodiesterases. Furthermore, the present invention pertains to the methods of manufacturing these Benzyl-substituted tetracyclic heterocyclic compounds.
    本发明涉及苄基取代的四环杂环化合物,以及由此产生的药物组合物,以及它们在治疗或预防通过抑制第5型磷酸二酯酶缓解的疾病中的应用。此外,本发明涉及制造这些苄基取代的四环杂环化合物的方法。
查看更多